Document is current

Article History

Accepted: 24 September 2024

First Online: 11 November 2024

Declarations

:

: No funds, grants, or other support was received.

: Dr. Patterson, Dr. Wagner, Dr. Salih, Ms. Shabazz, and Dr. Campbell were all employed by the National Pharmaceutical Council during their contributions to this article. The authors have no relevant financial or non-financial interests to disclose that are relevant to the content of this article and no financial or proprietary interests in any material discussed in this article.

: This study conducted a quantitative descriptive analysis of the publicly broadcasted and live-streamed patient-focused listening sessions held for the first ten drugs selected for the Drug Price Negotiation Program in October and November 2023. The publicly available transcripts of those sessions can be found at: .

: This study did not involve an intervention or interaction with the study subjects, used publicly available information, and did not analyze identifiable private information; accordingly, it was not considered human-subject research.

: Not applicable.

: Not applicable.

: The code used for analysis in this study can be made available upon request.

: The authors confirm their contribution to the paper as follows: Study conception and design: J.P, T.W., and J.C.; data collection: J.P., T.W., R.S., and G.S.; analysis and interpretation of results: J.P., T.W., and J.C.; and draft manuscript preparation: J.P., T.W., R.S., G.S., and J.C. All authors reviewed the results and approved the final version of the manuscript.